FBXL2 and non-small cell lung carcinoma: Given the important role of FBXL2-mediated EGFRT790M degradation in suppression of TKI-resistant NSCLC growth, we reasoned that targeting FBXL2 could be beneficial in the treatment of TKI-resistant NSCLC.